建立预后评分系统并探索I期非小细胞肺癌淋巴结数量的预后价值:一项监测、流行病学和最终结果(SEER)数据库和中国队列的回顾性研究。

IF 1.7 4区 医学 Q4 ONCOLOGY Translational cancer research Pub Date : 2025-01-31 Epub Date: 2025-01-23 DOI:10.21037/tcr-24-1474
Siyuan Wang, Xin Yin, Lingyun Wu, Hao Yu, Zhongjie Lu, Feng Zhao, Danfang Yan, Senxiang Yan
{"title":"建立预后评分系统并探索I期非小细胞肺癌淋巴结数量的预后价值:一项监测、流行病学和最终结果(SEER)数据库和中国队列的回顾性研究。","authors":"Siyuan Wang, Xin Yin, Lingyun Wu, Hao Yu, Zhongjie Lu, Feng Zhao, Danfang Yan, Senxiang Yan","doi":"10.21037/tcr-24-1474","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is currently no recognized assessment system to predict disease outcomes for stage I non-small cell lung cancer (NSCLC). This research aimed to develop a prognostic scoring system for predicting 5-year overall survival (OS) of individuals with stage I NSCLC following definitive therapeutic intervention. Additionally, the optimal number of examined lymph nodes (ELNs) count for tumors no larger than 30 mm was determined.</p><p><strong>Methods: </strong>Patients (n=22,617) diagnosed with stage I NSCLC from 2007 to 2015 who underwent definitive treatment (pulmonary lobectomy, pulmonary sublobectomy, or radiotherapy) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. There were 400 Chinese patients with stage I NSCLC diagnosed in 2017 enrolled for external validation. The nomogram was constructed based on gradient boosting machine. The optimal ELNs in patients with tumors ≤30 mm and node-negative undergoing pulmonary lobectomy or pulmonary sublobectomy were determined using log-rank test and validated by multivariable analysis.</p><p><strong>Results: </strong>Age at diagnosis, histology, differentiated grade, tumor staging, number of ELNs, and definitive treatment pattern were recognized as important factors for 5-year OS. The prognostic scoring system exhibited superior discrimination accuracy, calibration ability, and net clinical benefit compared to the tumor, node, metastasis (TNM) staging system. For patients with tumors ≤30 mm, more than 10 and 20 ELNs demonstrated the maximum OS difference during lobectomy and sublobectomy, respectively.</p><p><strong>Conclusions: </strong>This prognostic scoring system will anticipate the prognosis of stage I NSCLC patients after radical treatment, thereby offering individualized treatment recommendations for both clinicians and patients. A minimum of 10 ELNs during lobectomy and 20 ELNs during sublobectomy are necessary for small-sized NSCLC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"404-423"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833396/pdf/","citationCount":"0","resultStr":"{\"title\":\"Establishing a prognostic scoring system and exploring prognostic value of examined lymph node numbers for stage I non-small cell lung cancer: a retrospective study of Surveillance, Epidemiology, and End Results (SEER) database and a Chinese cohort.\",\"authors\":\"Siyuan Wang, Xin Yin, Lingyun Wu, Hao Yu, Zhongjie Lu, Feng Zhao, Danfang Yan, Senxiang Yan\",\"doi\":\"10.21037/tcr-24-1474\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There is currently no recognized assessment system to predict disease outcomes for stage I non-small cell lung cancer (NSCLC). This research aimed to develop a prognostic scoring system for predicting 5-year overall survival (OS) of individuals with stage I NSCLC following definitive therapeutic intervention. Additionally, the optimal number of examined lymph nodes (ELNs) count for tumors no larger than 30 mm was determined.</p><p><strong>Methods: </strong>Patients (n=22,617) diagnosed with stage I NSCLC from 2007 to 2015 who underwent definitive treatment (pulmonary lobectomy, pulmonary sublobectomy, or radiotherapy) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. There were 400 Chinese patients with stage I NSCLC diagnosed in 2017 enrolled for external validation. The nomogram was constructed based on gradient boosting machine. The optimal ELNs in patients with tumors ≤30 mm and node-negative undergoing pulmonary lobectomy or pulmonary sublobectomy were determined using log-rank test and validated by multivariable analysis.</p><p><strong>Results: </strong>Age at diagnosis, histology, differentiated grade, tumor staging, number of ELNs, and definitive treatment pattern were recognized as important factors for 5-year OS. The prognostic scoring system exhibited superior discrimination accuracy, calibration ability, and net clinical benefit compared to the tumor, node, metastasis (TNM) staging system. For patients with tumors ≤30 mm, more than 10 and 20 ELNs demonstrated the maximum OS difference during lobectomy and sublobectomy, respectively.</p><p><strong>Conclusions: </strong>This prognostic scoring system will anticipate the prognosis of stage I NSCLC patients after radical treatment, thereby offering individualized treatment recommendations for both clinicians and patients. A minimum of 10 ELNs during lobectomy and 20 ELNs during sublobectomy are necessary for small-sized NSCLC.</p>\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":\"14 1\",\"pages\":\"404-423\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833396/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tcr-24-1474\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1474","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:目前还没有公认的评估系统来预测I期非小细胞肺癌(NSCLC)的疾病结局。本研究旨在开发一种预后评分系统,用于预测I期非小细胞肺癌患者在明确治疗干预后的5年总生存期(OS)。此外,还确定了不大于30 mm的肿瘤的最佳检查淋巴结数(eln)计数。方法:从监测、流行病学和最终结果(SEER)数据库中确定2007年至2015年确诊为I期NSCLC的患者(n=22,617),这些患者接受了最终治疗(肺叶切除术、肺亚叶切除术或放疗)。2017年有400名中国I期非小细胞肺癌患者入组进行外部验证。基于梯度增强机构造了模态图。采用log-rank检验确定肿瘤≤30 mm且淋巴结阴性的肺叶切除术或肺亚叶切除术患者的最佳eln,并通过多变量分析进行验证。结果:诊断年龄、组织学、分化分级、肿瘤分期、eln数量、最终治疗方式是影响5年OS的重要因素。与肿瘤、淋巴结、转移(TNM)分期系统相比,预后评分系统表现出更高的识别准确性、校准能力和净临床效益。对于肿瘤≤30 mm的患者,超过10个和20个eln分别在肺叶切除术和叶下切除术中表现出最大的OS差异。结论:该预后评分系统可预测I期NSCLC患者根治后的预后,从而为临床医生和患者提供个性化的治疗建议。对于小体积NSCLC,在肺叶切除术中至少需要10个eln,在肺叶亚切除术中至少需要20个eln。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Establishing a prognostic scoring system and exploring prognostic value of examined lymph node numbers for stage I non-small cell lung cancer: a retrospective study of Surveillance, Epidemiology, and End Results (SEER) database and a Chinese cohort.

Background: There is currently no recognized assessment system to predict disease outcomes for stage I non-small cell lung cancer (NSCLC). This research aimed to develop a prognostic scoring system for predicting 5-year overall survival (OS) of individuals with stage I NSCLC following definitive therapeutic intervention. Additionally, the optimal number of examined lymph nodes (ELNs) count for tumors no larger than 30 mm was determined.

Methods: Patients (n=22,617) diagnosed with stage I NSCLC from 2007 to 2015 who underwent definitive treatment (pulmonary lobectomy, pulmonary sublobectomy, or radiotherapy) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. There were 400 Chinese patients with stage I NSCLC diagnosed in 2017 enrolled for external validation. The nomogram was constructed based on gradient boosting machine. The optimal ELNs in patients with tumors ≤30 mm and node-negative undergoing pulmonary lobectomy or pulmonary sublobectomy were determined using log-rank test and validated by multivariable analysis.

Results: Age at diagnosis, histology, differentiated grade, tumor staging, number of ELNs, and definitive treatment pattern were recognized as important factors for 5-year OS. The prognostic scoring system exhibited superior discrimination accuracy, calibration ability, and net clinical benefit compared to the tumor, node, metastasis (TNM) staging system. For patients with tumors ≤30 mm, more than 10 and 20 ELNs demonstrated the maximum OS difference during lobectomy and sublobectomy, respectively.

Conclusions: This prognostic scoring system will anticipate the prognosis of stage I NSCLC patients after radical treatment, thereby offering individualized treatment recommendations for both clinicians and patients. A minimum of 10 ELNs during lobectomy and 20 ELNs during sublobectomy are necessary for small-sized NSCLC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
期刊最新文献
RNAscope-based HER2 mRNA detection shows high concordance with fluorescence in situ hybridization in invasive breast carcinoma: a retrospective study. Identification and validation of a sphingolipid metabolism-related prognostic signature for predicting prognosis and immune microenvironment-related characteristics in ovarian cancer. SERPINH1, a regulatory factor of oligodendroglioma cell invasion and extracellular matrix secretion, as a novel prognostic biomarker and therapeutic target. Identification of papillary thyroid carcinoma-associated epithelial cell subpopulations and diagnostic biomarkers: integrating machine learning with single-cell analysis. GPR176 represses mitophagy to promote the progression of osteosarcoma by facilitating mTORC1 activity via PI3K-AKT pathway.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1